Erratum: Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin (J Thromb Thrombolysis (DOI 10.1007/s11239-012-0762-2));Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin

Journal of Thrombosis and Thrombolysis

Volumn 34, Issue 4, 2012, Pages 429-436

  Liang, Yan ^a,b   Johnston, Marilyn ^c   Hirsh, Jack ^d   Pare, Guillaume ^b   Li, Chunjian ^e   Mehta, Shamir ^b   Teo, Koon K ^b   Sloane, Debi ^b   Yi, Qilong ^f   Zhu, Jun ^a   Eikelboom, John W ^b  

^a FUWAI HOSPITAL   (China)

^b MCMASTER UNIVERSITY   (Canada)

^c HENDERSON RESEARCH CENTRE   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e NANJING MEDICAL UNIVERSITY   (China)

^f CANADIAN BLOOD SERVICES   (Canada)

Author keywords

Active metabolite concentration; ADP induced platelet aggregation; Clopidogrel; Correlation

Indexed keywords

EID: 84868207441     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0816-5     Document Type: Erratum

References (32)

1. Bassand JP, Hamm CW, Ardissino D et al (2007) Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28:1598-1660 (Pubitemid 47355992)
2. Van de Werf F, Bax J, Betriu A et al (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the task force on the management of ST-Segment elevation acute myocardial infarction of the European Society of cardiology. Eur Heart J 29:2909-2945
3. Anderson JL, Adams CD, Antman EM et al (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 116:e148-e304
4. Kushner FG, Hand M, Smith SC Jr et al (2009) 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 120:2271-2306
5. Hirsch AT, Haskal ZJ, Hertzer NR et al (2006) ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113:e463-e654
6. Sacco RL, Adams R, Albers G et al (2006) Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 37:577-617
7. De Miguel A, Ibanez B, Badimón JJ (2008) Clinical implications of clopidogrel resistance. Thromb Haemost 100:196-203
8. Wallentin L (2009) P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 30:1964-1977
9. Tuffal G, Roy S, Lavisse M, Brasseur D, Schofield J, Delesque Touchard N, Savi P, Bremond N, Rouchon MC, Hurbin F, Sultan E (2011) An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma. Thromb Haemost 105(4):696-705
10. Takahashi M, Pang H, Kawabata K et al (2008) Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS. J Pharm Biomed Anal 48(4):1219-1224
11. Heestermans AA, van Werkum JW, Schömig E, ten Berg JM, Taubert D (2006) Clopidogrel resistance caused by a failure to metabolize clopidogrel into its metabolites. J Thromb Haemost 4:1143-1145
12. Erlinge D, Varenhorst C, Braun OO, James S, Winters KJ, Jakubowski JA, Brandt JT, Sugidachi A, Siegbahn A, Wallentin L (2008) Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol 52:1968-1977
13. Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA, Sugidachi A, Winters KJ, Siegbahn A (2008) Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 29:21-30
14. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, Jakubowski JA, Naganuma H, Winters KJ((2007) A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 153(1):66.e9-66.e16 (Pubitemid 44895531)
15. Li YG, Ni L, Brandt JT et al (2009) Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. Platelets 20(5):316-327
16. Paniccia R, Antonucci E, Maggini N et al (2009) Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am J Clin Pathol 131(6):834-842
17. Tóth O, Calatzis A, Penz S et al (2006) Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 96(6):781-788 (Pubitemid 44883819)
18. Blindt R, Stellbrink K, de Taeye A et al (2007) The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 98:1329-1334 (Pubitemid 350239106)
19. Bonello L, Bonello-Palot N, Armero S, Bonello C, Mokhtar OA, Arques S, Dignat-George F, Camoin-Jau L, Paganelli F (2010) Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients. Thromb Res 125(4):e167-e170
20. Bouman HJ, Parlak E, van Werkum JW, Breet NJ, ten Cate H, Hackeng CM, ten Berg JM, Taubert D (2010) Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost 8:482-488
21. Dunn Graham (2008) Statistical evaluation of measurement errors. Design and Analysis of Reliability Studies, 2nd edn. Oxford University Press Inc, New York
22. Dunn G (1992) Review papers: design and analysis of reliability studies. Stat Methods Med Res 1:123-157
23. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1(8476):307-310 (Pubitemid 16134762)
24. Brazdzionyte J, Macas A (2007) Bland-Altman analysis as an alternative approach for statistical evaluation of agreement between two methods for measuring hemodynamics during acute myocardial infarction. Medicina (Kaunas) 43(3):208-214
25. Donner A, Zou G (2002) Testing the equality of dependent intraclass correlation coefficients. The Statistician 51(Part 3):367-379
26. Shuldiner AR, O'Connell JR, Bliden KP et al (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849-857
27. Sibbing D, Stegherr J, Latz W et al (2009) Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 30(8):916-922
28. Delavenne X, Mallouk N, Piot M, Mismetti P, Laporte S (2010) Is there really a relationship between the plasma concentration of the active metabolite of clopidogrel and the results of platelet function tests? J Thromb Haemost 8:2334-2338
29. Varenhorst C, Erlinge D, Braun OO, Brandt JT, Winters KJ, Jakubowski JA, Olofsson S, Wallentin L, Siegbahn A (2009) Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. Am Heart J 157(3):562.e1-562.e9
30. Cuisset T, Frere C, Poyet R, Quilici J, Gaborit B, Bali L, Brissy O, Lambert M, Morange PE, Alessi MC, Bonnet JL (2010) Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. Arch Cardiovasc Dis 103(1):39-45
31. Lordkipanidzé M, Pharand C, Nguyen TA, Schampaert E, Palisaitis DA, Diodati JG (2008) Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 29(23):2877-2885
32. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW (2011) The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent. Thromb Res 128(4):352-357